Skip to main content
. 2023 May 17;15(5):342. doi: 10.3390/toxins15050342

Figure 1.

Figure 1

Numbers within or above the circles reflect subject records available for neutralizing antibody evaluation at each treatment cycle (95% of subjects received 1–9 cycles) by approved indication, Indications are ordered by year of onabotulinumtoxinA approval, with approval year in parentheses. Circle sizes are proportional to the number of patient records indicated.